>Goal— The goal of this program is to educate pharmacists about the use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (df) combination tablet for the treatment of HIV infection.>Objectives—At the completion of this program, the reader will be able to: class="enumerated" style="list-style-type:decimal">Describe the pharmacology and pharmacokinetics of elvitegravir/cobicistat/emtricitabine/tenofovir df combination.Discuss the risks associated with the use of elvitegravir/cobicistat/emtricitabine/tenofovir df combination.Discuss the potential benefit of elvitegravir/cobicistat/emtricitabine/tenofovir df combination for an individual patient.Apply the information on the use of elvitegravir/cobicistat/emtricitabine/tenofovir df combination to a case study.
展开▼
